

Inhibitory effects of captopril on *c-myc* expression during left ventricular hypertrophy¹

SU Jin-Zi², CHEN Da-Guang, WU Ke-Gui, CHEN Song-Cang³, HU Wen-Yang⁴, WANG Xiang-Yu, RUI Hong-Bing⁵, WANG Hua-Jun, XU Chang-Sheng (Department of Cardiology, First Affiliated Hospital of Fujian Medical University, Fujian Institute of Hypertension, Fuzhou 350005, China)

KEY WORDS left ventricular hypertrophy; proto-oncogenes; proto-oncogene proteins *c-myc*; angiotensin II; captopril; inbred SHR rats; hypertension; Northern blotting; Western blotting; immunohistochemistry

AIM: To study the molecular mechanism of captopril (Cap) on the inhibition of left ventricular hypertrophy (LVH), disclose the expression and distribution of *c-myc* in different cell types in left ventricle (LV) in spontaneously hypertensive rats (SHR). **METHODS:** Cap 100 mg · kg⁻¹ · d⁻¹ was given *po* to SHR. Systolic blood pressure (SBP), left ventricular weight (LVW), and body weight (BW) were measured at 16-wk old. The level of angiotensin II (Ang II), *c-myc* mRNA, and oncoprotein were determined by immunohistochemical method, Northern blot, and Western blot, respectively. **RESULTS:** Cap reduced SBP, LVW/BW in SHR, with a decrease of Ang II and *c-myc* expression in LV. Local cardiac Ang II mainly distributed in cardiomyocytes. Cap inhibited cardiac Ang II production and *c-myc* expression (histochemical staining intensity index, 0.49 ± 0.04 vs 0.83 ± 0.24, *P* < 0.01). The *c-myc* oncoprotein was prevalently located in cardiac fibroblasts. The *c-myc* oncoprotein in Cap treated SHR was lower than that of WKY. **CONCLUSION:** High expression of *c-myc* in fibroblasts played an important role in the development of LVH in SHR. Inhibitory effects of Cap on LVH was associated with a decreased myocardial Ang II and

interstitial fibroblasts *c-myc* expression. The *c-myc* oncoprotein post-transcriptional translation was also interrupted by Cap.

Left ventricular hypertrophy (LVH) in essential hypertension is a result of hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts along with abnormal accumulation of fibrillar collagen in extracellular space and has been speculated as a response to abnormal expression of a series of hypertension-related genes^[1]. Abnormal increasing of local cardiac angiotensin II (Ang II), a result of the activation of cardiac renin-angiotensin system (RAS), plays an important role in the pathological process of LVH. *In vitro*, Ang II induced an immediately, transiently increased expression of proto-oncogene *c-myc*, which had been supposed to be a common response to mitogenic stimulation^[2], in cultured cardiomyocytes and fibroblasts. Increasing *c-myc* expression resulted in hypertrophy in cultured cardiomyocytes and hyperplasia in fibroblasts^[3]. The role of *c-myc* in inducing LVH had been also proved by transgenic and antisense oligonucleotide techniques^[4]. The previous work^[5] in our laboratory has demonstrated that captopril (Cap) could effectively reverse LVH, which is associated with decreased *c-myc* but not *c-fos* proto-oncogene expression in left ventricle in SHR. However, it was yet unknown that the high expression of *c-myc* originated from cardiac myocytes or fibroblasts. This paper was to investigate the exact location of *c-myc* expression in LV, and to disclose the effect of cap on the alteration of *c-myc* expression in various types of cell population in LV.

MATERIALS AND METHODS

Rats Rats were offsprings of breeders derived from Shanghai Institute of Hypertension. Parental ♀ and ♂ adult SHR rats were matched

¹ Project supported by the National Natural Science Foundation of China. No 39270329.

² Correspondence to Dr SU Jin-Zi. Pm 86-591-335-7199, ext 756 or 324. Fax 86-591-331-8716. E-mail sujinzhi@163.net

³ Now in Metabolism Research Unit, University of California, San Francisco, CA 94143, USA.

⁴ Now in Second Department of Internal Medicine, Nihon University School of Medicine, Tokyo 173, Japan.

⁵ Now in Department of Hematology, First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.

Received 1996-12-16

Accepted 1998-03-25

in cages, Cap $100 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ was given *po* in solid mixture with small amount milk powder, the ♀ SHR rats were maintained at this dosage throughout pregnancy and lactation. The ♂ weaned pups ($n = 28$) continued the treatment until 16 wk of age. Only milk was given to sex- and age-matched untreated SHR ($n = 27$) and WKY controls ($n = 28$). Experiments were performed on ♂ rats at 16 wk.

Drugs and chemicals Cap was purchased from Sino-American Shanghai Squibb Pharmaceutical Ltd. Chemicals for RNA extraction and diaminobenzidine (DAB) were purchased from Sigma Co. Agarose, random primer kit and T_4 polynucleotide kinase were from Promega Co (Madison WI, USA). 3-[*N*-Morpholino] propano-sulfonic acid and nylon membrane were obtained from Boehringer Co. Nitricellulose (NC) membrane was from Hybond™ (Germany), Nucletrac™ Push column from Stratagene Co (La Jolla CA), [α - ^{32}P]dCTP and [γ - ^{32}P]ATP were from Beijing Furei Co. Rat *c-myc* cDNA probes were obtained from Institute of Cardiovascular Basic Research of Beijing Medical University. 18S oligonucleotide probe was a gift from Dr CHEN Yiu-Fai (University of Alabama, USA). Monoclonal *c-myc* primary antibody was from Santa Cruz Biotechnology, Inc (USA), biotin labeled anti-IgG and SA-HRP were from Vector Co (USA). Other chemicals were of either AR or molecular biology grade.

Blood pressure (BP) and left ventricular weight (LVW) to body weight (BW) ratio measurement Systolic BP (SBP) was measured using tail-cuff technique (MRB-III A computer controlled sphygmomanometer for rats, Shanghai Institute of Hypertension) at 16 wk of age. Rats were weighed before decapitation, the heart was excised, left ventricle including interventricular septum was weighed. LVH was assessed by LVW/BW.

Immunohistochemical study Tissues from LV were fixed in 10 % formaldehyde, paraffin embedded. Sections with $6 \mu\text{m}$ thick were processed using streptavidin-peroxidase (SP) immunohistochemical method^[6]. Result of immunoreaction was visualized by reaction of horseradish peroxidase (HRP) and diaminobenzidine. Sections were restained with HE and examined under a light microscope (Olympus).

Nonspecific staining was ruled out by negative controls (without primary antibody).

RNA extraction and Northern blot Total RNA was prepared^[7] from a block of left ventricle (weighed 0.6 to 1.0 g). The quantity and purity of obtained total RNA were determined by measuring the A_{260} and A_{280} at $\lambda_{260 \text{ nm}}$ and $\lambda_{280 \text{ nm}}$, respectively. Each sample containing the same amount (approximate $50 \mu\text{g}$) of total RNA was loaded. Denaturing gel electrophoresis of RNA was done to confirm the purity of extracted RNA and for further experiments. Then RNA was transferred onto nylon membranes. The membranes were prehybridized in formamide buffer (50 % formamide, $5 \times$ SSPE, $2 \times$ Denhart's buffer, 0.1 % SDS, SSPE; $\text{NaCl } 7.5 \text{ mmol} \cdot \text{L}^{-1}$, $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O } 0.55 \text{ mmol} \cdot \text{L}^{-1}$, edetic acid $0.1 \text{ mmol} \cdot \text{L}^{-1}$, pH 8.0. SDS: sodium lauryl sulfete. Denhart's buffer: 0.02 % Ficoll, 0.02 % polyvinylpyrrolidone, 0.02 % BSA) at $42 \text{ }^\circ\text{C}$ for at least 2 h. Hybridization was performed at $42 \text{ }^\circ\text{C}$ for 24 h using the same buffer containing the appropriated α - ^{32}P labeled *c-myc* cDNA probe prepared by random priming procedure. Unhybridized probe was removed from the nylon membranes with high stringency procedure ($2 \times$ SSC/0.1 % SDS at $37 \text{ }^\circ\text{C}$ for 15 min, twice; $0.1 \times$ SSC/0.1 % SDS at $37 \text{ }^\circ\text{C}$ for 15 min, twice; $0.1 \times$ SSC/0.1 % SDS at $55 \text{ }^\circ\text{C}$ for 30 min, twice. SSC: $\text{NaCl } 150 \text{ mmol} \cdot \text{L}^{-1}$, sodium citrate $15 \text{ mmol} \cdot \text{L}^{-1}$, pH 7.0). The membranes were exposed to Fuji X-ray Film for 2 - 3 d at $-70 \text{ }^\circ\text{C}$. To control the possible samples variability, the membranes were washed in $0.1 \times$ SSC/0.1 % SDS at $95 \text{ }^\circ\text{C}$ for 5 min to remove hybridized radioactive probes. The membranes were rehybridized by [γ - ^{32}P]labeled 18S oligonucleotide probe as an internal standard. Relative amount of specific mRNA was determined by densitometric scanner (Beckman Appraise™ Densitometer, USA). The densitometric scores of specific mRNA were normalized by that of 18S rRNA.

Protein extraction and Western blot^[8] Briefly, tissue samples, placed in SDS sample buffer (Tris $25 \text{ mmol} \cdot \text{L}^{-1}$, $\text{NaCl } 50 \text{ mmol} \cdot \text{L}^{-1}$, 0.5 % sodium deoxycholate, 1 % nonidet P-40, 0.1 % SDS, phenylmethyl sulfonyl fluoride

1 mmol · L⁻¹, aprotinin 500 kU · L⁻¹) were homogenized, sonicated, and then centrifuged at 30 000 × *g*, 4 °C for 30 min. The supernatant was boiled for 10 min and protein concentration was measured, then subjected to SDS-PAGE electrophoresis. Samples containing equal 200 μg protein from each rat were loaded per lane. After the transfer of protein onto nitrocellulose filters, the filters were incubated for 1 h in phosphate-buffered saline/0.5 % Tween 20 (PBS-T, PBS: NaH₂PO₄ 15 mmol · L⁻¹, Na₂HPO₄ 80 mmol · L⁻¹, NaCl 1.5 mol · L⁻¹, pH 7.5) containing 5 % nonfat dry milk. Immunological evaluation was performed as followed: filter was incubated at 25 °C for 1 h in 1 % BSA/PBS-T buffer containing mouse monoclonal antibody against *c-myc* protein 10 mg · L⁻¹, washed with PBS-T and incubated for 30 min with biotin labeled goat anti-mouse IgG antibody, washed again and reacted with streptavidin again. After extensive washing with PBS-T, the immunocomplexes on the filters were visualized for 1 min with diaminobenzidine (DAB). Finally, the filters were photographed and subjected to densitometric analysis (Beckman AppraiseTM Densitometer, USA).

Statistical analysis Data were expressed as $\bar{x} \pm s$. Student-Newman Keuls procedure in Statistical Package for the Social Science (SPSS) was used to evaluate the differences between Cap treated SHR, untreated SHR, and WKY groups.

RESULTS

Cap prevented the development of hypertension and LVH in SHR At 16 wk of age, SBP in Cap treated SHR (*n* = 28) was lower than that of untreated SHR (*n* = 27), (18.8 ± 2.6) *vs* (25.7 ± 2.7) kPa, (*P* < 0.01), but still higher than that of WKY (*n* = 28), (18.8 ± 2.6) *vs* (16.2 ± 1.8) kPa, (*P* < 0.01). LVW/BW in SHR was markedly greater than that of WKY (3.6 ± 0.4) *vs* (2.5 ± 0.3) mg · g⁻¹, (*P* < 0.01). Cap prevented the development of LVH in SHR [LVW/BW: (2.61 ± 0.20) *vs* (3.6 ± 0.4) mg · g⁻¹, *P* < 0.01] (Tab 1).

Local cardiac Ang II was mainly produced by cardiomyocytes and was reduced by Cap treatment Immunohistochemical staining showed that cardiac Ang II was predo-

Tab 1. Systolic blood pressure (SBP) and left ventricular weight to body weight ratio (LVW/BW) in Cap treated SHR (SHRcap), untreated SHR, and WKY rats at 16-wk old. $\bar{x} \pm s$. ^c*P* < 0.01 *vs* SHR. ^f*P* < 0.01 *vs* WKY.

	SHR (27 rats)	SHRcap (28 rats)	WKY (28 rats)
SBP, kPa	25.7 ± 2.7	18.8 ± 2.6 ^{c,f}	16.2 ± 1.8
LVW/BW, mg · g ⁻¹	3.6 ± 0.4	2.61 ± 0.20 ^f	2.5 ± 0.3

minantly localized in cardiomyocytes. In SHR, local cardiac Ang II was apparently higher than that of WKY (histochemical staining intensity index, HSII: 0.83 ± 0.24 *vs* 0.45 ± 0.03, *n* = 12, *P* < 0.01). Cap inhibited cardiac Ang II production of SHR (HSII: 0.49 ± 0.04 *vs* 0.83 ± 0.24, *n* = 12, *P* < 0.01) to a level approximate to that of WKY (HSII: 0.49 ± 0.04 *vs* 0.45 ± 0.03, *n* = 12, *P* > 0.05) (Fig 1, Plate 1).

Cap inhibited *c-myc* mRNA expression and oncoprotein in LV of SHR Expression of *c-myc* mRNA in LV of SHR was 2.03-fold higher than that of WKY, Cap inhibited *c-myc* expression (arbitrary OD units, 0.92 ± 0.17 *vs* 1.69 ± 0.21, *n* = 8, *P* < 0.01), but it was still higher than that of WKY (arbitrary OD units, 0.92 ± 0.17 *vs* 0.56 ± 0.12, *n* = 8, *P* < 0.01) (Fig 2).




Fig 2. Northern blot showing the expression of proto-oncogene *c-myc* mRNA in LV in SHR, Cap treated SHR (SHRcap), and WKY rats at 16 wk of age. Rehybridization of the same blot with 18S rRNA probe, serving as internal standard, indicated the amount of total RNA was loaded in each lane (bottom). Each group *n* = 8 rats.

Western immunoblotting was not totally coincident with Northern blot. Oncoprotein of *c-myc* in SHRcap was lower not only than that

of SHR, (OD value: 2.1 ± 0.4 vs 20 ± 6 , $n = 8$, $P < 0.01$), but also than that of WKY (OD value, 2.1 ± 0.4 vs 10.9 ± 1.4 , $n = 8$, $P < 0.01$) (Fig 3).




Fig 3. Western blot showing the levels of oncoprotein *c-myc* in LV in SHR, Cap treated SHR (SHRcap), and WKY rats (each group $n = 12$) at 16-wk old. Each lane contained 200 μg total protein.

***c-myc* Oncoprotein mainly located in cardiac fibroblasts** *c-myc* Oncoprotein was mainly located in the nuclei of fibroblasts. The HSII of *c-myc* in fibroblasts was 2.61 folds of that in cardiac myocytes (Fig 1, Plate 1, Tab 2).

Tab 2. Oncoprotein *c-myc* in cardiomyocytes and cardiac fibroblasts in LV of Cap treated SHR (SHRcap), untreated SHR and WKY rats at 16-wk old. Results were assessed by histochemical staining intensive index (HSII).

Each group $n = 8$ rats. $\bar{x} \pm s$.

^a $P < 0.01$ vs SHR. ^b $P > 0.05$, ^c $P < 0.01$ vs WKY.

	SHR	SHRcap	WKY
Myocytes	1.0 ± 0.3	0.44 ± 0.23^{cd}	0.6 ± 0.4
Fibroblasts	2.61 ± 0.11	0.21 ± 0.10^{cd}	0.53 ± 0.11

Elevated *c-myc* expression, critical to the development of LVH There was a positive correlation between LVW/BW and *c-myc* mRNA ($r = 0.97$, $P < 0.01$) (Fig 4). No correlation showed between SBP and LVW/BW ($r = 0.0335$, $P = 0.93$), or *c-myc* mRNA and SBP ($r = -0.419$, $P = 0.915$).

DISCUSSION

Present study demonstrated the underlying interaction between cardiomyocytes and cardiac fibroblasts in promoting LVH and the correlation in the reversal of LVH and depressed expression of proto-oncogene *c-myc* by Cap treatment. We found that cardiac Ang II was mainly located in cardiomyocytes but little in fibroblasts. This seemed to indicate that cardiomyocytes were more




Fig 4. Correlation between left ventricular weight to body weight ratio (LVW/BW) and the arbitrary OD units of *c-myc* mRNA expression in LV of SHR ($n = 9$, $r = 0.97$, $P < 0.01$).

critical to the development of LVH than fibroblasts. However, the fact was that collagen usually grew faster than cardiomyocytes in LV of SHR, resulting in fibrosis in LV^[9]. Ang II functions through angiotensin type 1 receptor (AT_1)^[10]. In cardiac fibroblasts, but not in myocytes, there existed high affinity and density of AT_1 receptor in relation to high level of AT_1 receptor mRNA expression in neonatal rat heart^[11]. The different distribution in Ang II and its functional receptor between fibroblasts and cardiomyocytes suggested a potential role for the fibroblasts in mediating the effect of Ang II in the heart. The proliferation of cardiac fibroblasts and subsequential collagen synthesis may be resulted from Ang II stimulation paracrine by cardiac myocytes. Increasing Ang II in LV, on the other hand, inhibited the activity of collagenase, or matrix metalloproteinase, a critical enzyme for degradation of collagen, which eventually increased the accumulation of collagen^[12]. A transiently, immediately increasing expression of proto-oncogene *c-myc* was demonstrated as a common response to hormonal and mechanical stimuli^[2]. However, our data, together with other investigators^[4], demonstrated that well developed LVH in SHR was accompanied by persistent high expression of *c-myc* mRNA. We also confirmed this result at post-transcriptional level and further found *c-myc* oncoprotein was predominately located in the nuclei of cardiac fibroblasts. The mechanism of such different *c-myc* expression styles between

myocytes and nonmyocytes remains obscure. *c-myc* had been reported to be expressed in G₀ phase in cell growth cycle^[14]. Impotence in mitosis of postnatal cardiomyocyte may be produced by the loss of stimulating growth factor, or transducer or acquisition inhibitory factors^[15], thus limiting cell division and *c-myc* expression. In contrast to cardiomyocytes, cardiac fibroblasts are undergoing constant hyperplasia responding to Ang II stimulation resulting in a longlasting expression of *c-myc*.

Cap was effective in the reversal of left ventricular hypertrophy, which was associated with a decreased level of local cardiac Ang II^[14]. Our data showed a significant decrease of Ang II content in myocyte and *c-myc* expression in fibroblasts. Decrease in Ang II contributed to the regression of hypertrophy in cardiac myocytes and further prevented hyperplasia in fibroblasts. Except for these, the inhibitory effects of Cap on LVH may also benefit from a descendant blood pressure and removal of the inhibition on metalloproteinase by Ang II. Surprisingly, *c-myc* oncoprotein was inhibited to a level even lower than that of its normotensive control. The exact mechanism of this phenomenon remains to be further studied.

This study explored an underlying molecular mechanism of LVH confirming that the initial activation of cardiac renin-angiotensin system critically triggered LVH. Ang II dominantly induced *c-myc* expression in cardiac fibroblasts which resulted in heart hypertrophy. Cap effectively inhibited Ang II production and subsequent *c-myc* expression, thus preventing the development of LVH.

REFERENCES

- 1 Yang YD, Li QH, Zhang XB. Advances in identifying the genes relating to essential hypertension. *Chin J Hypertens* 1993; 1: 1-4.
- 2 Rosenwald IB, Rhoads DB, Callanan LD, Isselbacher KJ, Schmidt EV. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 α in response to growth induction by *c-myc*. *Proc Natl Acad Sci USA* 1993; 90: 6175-8.
- 3 Sadoshima J-i, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts; critical role of the AT₁ receptor subtype. *Circ Res* 1993; 73: 413-23.
- 4 Jackson T, Allard MF, Sreenan CM, Doss LK, Bishop SP, Swain JL. The *c-myc* proto-oncogene regulates cardiac

development in transgenic mice.

Mol Cell Biol 1990; 10: 3709-16.

- 5 Chen SC, Chen DG, Bao YD, Jin XQ, Lin YQ, Wang HJ. Inhibition of left ventricular hypertrophy and expression of proto-oncogenes *c-myc* other than *c-fos* in myocardium by early captopril treatment in SHR rats. *Acta Pharmacol Sin* 1995; 16: 217-22.
- 6 Zou XJ, Cai L, Cai MX, Ni CR, Wei YL. Relation between the expression of oncogene *ras* and cell growth cycle in cervical carcinoma cell. *J Clin Exp Pathol* 1995; 11: 187-8.
- 7 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987; 162: 156-9.
- 8 Wang JY, Johnson LR. Expression of protooncogenes *c-fos* and *c-myc* in healing of gastric mucosal stress ulcers. *Am J Physiol* 1994; 266: G878-86.
- 9 Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. *Circ Res* 1989; 64: 1041-50.
- 10 Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by AT₁ receptor. *Am J Hypertens* 1992; 5 (5 Pt 1): 276-80.
- 11 Kim NN, Villarreal FJ, Printz MP, Lee AA, Dillmann WH. Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. *Am J Physiol* 1995; 269: E426-37.
- 12 Brilla CG, Maisch B, Zhou G, Weber KT. Hormonal regulation of cardiac fibroblast function. *Eur Heart J* 1995; 16 Suppl C: 45-50.
- 13 Dani CH, Mechti N, Piechaczyk M, Lebleu B, Jeanteur PH, Blanchard JM. Increased rate of degradation of *c-myc* mRNA in interferon-treated Daudi cells. *Proc Natl Acad Sci USA* 1985; 82: 4896-9.
- 14 Samuel JL, Dubus I, Contard F, Schwartz K, Rappaport L. Biological signals of cardiac hypertrophy. *Eur Heart J* 1990; 11 Suppl G: 1-7.
- 15 Hu WY, Chen DG, Chen SC, Jin XQ, Wang HJ. Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats. *Acta Pharmacol Sin* 1996; 17: 507-12.

535-540

卡托普利抑制原癌基因 *c-myc* 在左心室肥大时的表达¹

苏津自², 陈达光¹, 吴可贵, 陈松苍³, 胡文养⁴,
王向宇, 芮红兵⁵, 王华军, 许昌声 R 972 4
(福建医科大学附属第一医院心血管内科, 福建省高血压研究所, 福州 350005, 中国)

关键词 左心室肥大; 原癌基因类; 原癌基因蛋白 *c-myc*; 血管紧张素 II; 卡托普利; 近交 SHR 大鼠; 高血压; RNA 印迹; 蛋白质印迹; 免疫组织化学

目的: 观察卡托普利(Cap)对原癌基因 *c-myc* 在自发性高血压大鼠(SHR)左心室心肌不同细胞类型的表达的影响, 探讨 Cap 抑制左心室肥大的分子机制。方法: SHR 宫内期口服给药($100 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$), 雄性 SHR 16 周龄时测定收缩压、左室重与体重比。左心室 *c-myc* mRNA, Ang II 及 *c-myc* 癌

蛋白表达量分别用 RNA 印迹、免疫组化及蛋白质印迹测定。结果: Cap 明显降低 SHR 大鼠的收缩压, 抑制左心室肥大及 *c-myc* 表达, 心肌局部 Ang II 主要产生于心肌细胞, *c-myc* 则主要源于成纤维细胞。结论: Cap 通过抑制心肌细胞的 Ang II 和成纤维细胞的 *c-myc* 表达而逆转左心室肥大。

Effects of genistein on aggregation and cytosolic free calcium in pig platelets¹

LIU Wen², SONG Zhi-Juan, LIANG Nian-Ci

(Institute of Medical Biochemistry, Guangdong Medical College, Zhanjiang 524023, China)

KEY WORDS isoflavones; genistein; thrombin; platelet aggregation; calcium; protein-tyrosine kinase

AIM: To study the effects of genistein on aggregation and cytosolic free calcium concentration in platelets. **METHODS:** Using turbidimetry to analyse aggregation and using Fura-2 fluorescence technique to determine Ca^{2+} level. **RESULTS:** Genistein strongly inhibited the pig platelet aggregation induced by thrombin ($250 \text{ U} \cdot \text{L}^{-1}$). When genistein concentrations were 5 and $20 \mu\text{mol} \cdot \text{L}^{-1}$, the inhibition rates on the aggregation were 52 % and 73 %, respectively. Genistein inhibited the rise of cytosolic free calcium concentration in platelets stimulated by thrombin ($500 \text{ U} \cdot \text{L}^{-1}$) in the presence of extracellular $\text{Ca}^{2+} 1 \text{ mmol} \cdot \text{L}^{-1}$. When genistein concentrations were 10, 20, 40, and $80 \mu\text{mol} \cdot \text{L}^{-1}$, the inhibition rates were 24 %, 40 %, 63 %, and 65 %, respectively, but no effect on thrombin-induced internal Ca^{2+} release from dense tubular system. **CONCLUSION:** Genistein is a potential anti-platelet agent, mainly due to an inhibition of Ca^{2+} influx.

Genistein (4,5,7-trihydroxyisoflavone) is a specific inhibitor of tyrosine protein kinase (TPK)⁽¹⁾. It inhibits platelet shape change and

protein tyrosine phosphorylation in platelet⁽²⁾. In the present study, we investigated the effect of genistein on thrombin-induced pig platelet aggregation.

MATERIALS AND METHODS

Thrombin, egtazic acid, Fura 2-AM, Triton X-100, bovine serum albumin (BSA), RPMI 1640, and genistein were from Sigma. All other chemicals were AR.

Pig blood collected in plastic tubes and anticoagulated with 0.15 volume of ACD (trisodium citrate 86, glucose 111, citric acid $53 \text{ mmol} \cdot \text{L}^{-1}$).

Platelet aggregation Pig blood was spun at $200 \times g$ for 15 min, and the supernatant was then spun at $800 \times g$ for 10 min. The cells were resuspended at 2×10^{11} platelets $\cdot \text{L}^{-1}$ in Tyrode-HEPES buffer (NaCl 140, KCl 5, $\text{MgSO}_4 1$, HEPES 10, glucose $10 \text{ mmol} \cdot \text{L}^{-1}$, pH 7.4). Platelet aggregometry was carried by an SPA-4 aggregometer (Shanghai). The platelet suspensions (0.2 mL) were incubated with genistein for 2 min, and then stimulated with thrombin $250 \text{ U} \cdot \text{L}^{-1}$ for 3 min.

Cytosolic free calcium Suspensions of 2×10^{11} platelets $\cdot \text{L}^{-1}$ in an RPMI-1640 (pH 7.4) containing 0.2 % BSA and HEPES $10 \text{ mmol} \cdot \text{L}^{-1}$ were incubated with Fura 2-AM $2.5 \mu\text{mol} \cdot \text{L}^{-1}$ at $25 \text{ }^\circ\text{C}$ for 45 min. The cell suspension was then spun at $800 \times g$ for 10 min. The resuspension was of $3 \times 10^{10} - 4 \times 10^{10}$ platelets $\cdot \text{L}^{-1}$ in a Tyrode-HEPES buffer. Fluorescence

¹ Project supported by Guangdong Research Foundation for Key Field, No 9306.

² Correspondence to LIU Wen, MS. Pfn 86-759-238-8532.
Received 1998-04-08 Accepted 1998-04-25